 |
|
Deadly dose: Rensselaer heparin expert helps uncover source of lethal contamination
April 28, 2008Troy, N.Y. -- The mysterious death of patients around the world following a routine dosage of the common blood thinner, heparin, sent researchers on a frantic search to uncover what could make the standard drug so toxic. A researcher at Rensselaer Polytechnic Institute was among a small group of scientists with the expertise and the high-tech equipment necessary to determine the source of the contamination.
Robert J. Linhardt, the Ann and John H. Broadbent Jr. '59 Senior Constellation Professor of Biocatalysis and Metabolic Engineering at Rensselaer, is part of an international team that recently announced it had uncovered the source of the deadly contamination. On April 23, the team led by researchers at the Massachusetts Institute of Technology (MIT), described the source in the journal Nature Biotechnology -- a complex carbohydrate named oversulfated chondroitin sulfate, which has a structure so similar to heparin it was nearly undetectable to less advanced technology.
"Days after the deaths were first linked to heparin, we had the drugs in our hands from the FDA and our nuclear magnetic resonator (NMR) was set into motion to break down the structure of the drug and determine what could possibly be the source of the contamination," Linhardt said. "Now that we know the most likely source of the contamination, we are developing much stronger monitoring systems to ensure that this type of contamination is detected before it reaches patients."
Although extremely close in chemical structure to heparin, the contaminant caused severe allergic reaction in many patients who were receiving routine treatment for kidney dialysis, heart surgery, and other common medical issues. The researchers' extremely detailed structural analysis of the drug, using technology such as the NMR, was able to detect the minute differences between the contaminated drug and a normal dosage of heparin. And while Linhardt and others are developing more sophisticated detection systems, Linhardt also is helping lead the race for a safer, man-made alternative to the traditional biologic heparin. Biological heparin is currently developed by purifying the scrapings of pig and cow intestines.
"This contamination is unfortunately a sign that the way we currently manufacture heparin is simply unsafe," he said. "Because we rely on animals, we open ourselves up for spreading prions and diseases like mad cow disease through these animals. And because most of the raw material is imported, we often can't be sure of exactly what we are getting."
Linhardt is helping lead the global race to develop a synthetic alternative to heparin that could help eliminate the potential for contamination and adverse affects of biologic heparin. His lab developed the first fully synthetic heparin in amounts large enough for human dosage in 2005, and he continues to work to get the product further tested and commercialized.
"A synthetic heparin is built using sugars and enzymes found in the human body," Linhardt said of his recipe for synthetic heparin. "So instead of taking pig intestines and trying to purify it over and over again to reduce it down to just heparin, we are building heparin from scratch with no foreign material present. This method ensures that we know exactly what is in the drug and have complete control over its ingredients."
Rensselaer Polytechnic Institute
Although extremely close in chemical structure to heparin, the contaminant caused severe allergic reaction in many patients who were receiving routine treatment for kidney dialysis, heart surgery, and other common medical issues. The researchers' extremely detailed structural analysis of the drug, using technology such as the NMR, was able to detect the minute differences between the contaminated drug and a normal dosage of heparin. And while Linhardt and others are developing more sophisticated detection systems, Linhardt also is helping lead the race for a safer, man-made alternative to the traditional biologic heparin. Biological heparin is currently developed by purifying the scrapings of pig and cow intestines.
"This contamination is unfortunately a sign that the way we currently manufacture heparin is simply unsafe," he said. "Because we rely on animals, we open ourselves up for spreading prions and diseases like mad cow disease through these animals. And because most of the raw material is imported, we often can't be sure of exactly what we are getting."
Linhardt is helping lead the global race to develop a synthetic alternative to heparin that could help eliminate the potential for contamination and adverse affects of biologic heparin. His lab developed the first fully synthetic heparin in amounts large enough for human dosage in 2005, and he continues to work to get the product further tested and commercialized.
"A synthetic heparin is built using sugars and enzymes found in the human body," Linhardt said of his recipe for synthetic heparin. "So instead of taking pig intestines and trying to purify it over and over again to reduce it down to just heparin, we are building heparin from scratch with no foreign material present. This method ensures that we know exactly what is in the drug and have complete control over its ingredients."
Rensselaer Polytechnic Institute
Heparin News and Current Heparin Events RSSChemists move closer toward developing safer, fully-synthetic form of heparin
Chemists are reporting a major advance toward developing a safer, fully-synthetic version of heparin, the widely used blood thinner now produced from pig intestines. The U. S. Food and Drug Administration last spring linked contaminated batches of the animal-based product, imported from China, to more than 80 deaths and hundreds of allergic reactions among patients exposed to the drug for kidney dialysis and other conditions.
Researchers create safer alternative to heparin
Robert Linhardt has spent years stitching together minuscule carbohydrates to build a more pure and safer alternative to the commonly used and controversial blood thinner heparin.
Maternal deaths following cesarean delivery can be reduced
Maternal death rates have remained constant in the United States for many decades. Are there any improvements in health care that could reduce these rates further?
New blood clot guidelines for pregnant women
New evidence-based guidelines address the prevention and management of thrombosis in key patient populations and reinforce recommendations related to the routine use of preventive therapies.
Avoiding Spleen Removal for Cooley's Anemia Sufferers
Researchers from Weill Cornell Medical College may have discovered the precise role of a gene in one of the world's most common blood disorders, beta-thalassemia, commonly known as Cooley's anemia.
Findings released from 1 of the largest percutaneous coronary intervention trials ever
A study led by Gregg W. Stone, M.D., professor of medicine at Columbia University Medical Center/NewYork-Presbyterian and chairman of the Cardiovascular Research Foundation, has shown that heart attack patients who were administered the direct thrombin inhibitor bivalirudin during primary angioplasty had a reduced rate of adverse clinical events, a lower rate of major bleeding, and a lower mortality rate than those who were treated with a regimen of heparin and glycoprotein IIb/IIIa inhibitors (GPI).
Landmark study reveals superiority of bivalirudin in heart attack patients at 30 days
The Cardiovascular Research Foundation (CRF) announced today that the New England Journal of Medicine published results of the HORIZONS AMI trial which showed the use of the anticoagulant bivalirudin following angioplasty in heart attack patients reduced net adverse clinical events by 24 percent compared to the standard treatment, as well as reduced the risk of overall mortality by 33 percent and cardiac mortality by 38 percent.
Commencement 2008: Undergrad Has Sweet Success With Invention of Artificial Golgi
An undergraduate student at Rensselaer Polytechnic Institute has learned very quickly that a spoonful of sugar really does help the medicine go down. In fact, with his invention, the sugar may actually be the medicine.
MIT-led teams unravel heparin death mystery
An international team of researchers led by MIT has explained how contaminated batches of the blood-thinner heparin were able to slip past traditional safety screens and kill dozens of patients recently in the United States and Germany.
Mayo Clinic identifies treatment target for liver cancer recurrence and survival
Deadly and difficult to treat, liver cancer has long resisted attempts by researchers to develop ways to prolong life and prevent recurrence.
More Heparin News Articles
 | Heparin - A Medical Dictionary, Bibliography, and Annotated Research Guide to Internet References by ICON Health Publications This is a 3-in-1 reference book. It gives a complete medical dictionary covering hundreds of terms and expressions relating to heparin. It also gives extensive lists of bibliographic citations. Finally, it provides information to users on how to update their knowledge using various Internet resources. The book is designed for physicians, medical students preparing for Board examinations, medical... |
 | Heparin-Induced Thrombocytopenia, Fourth Edition (Fundamental and Clinical Cardiology) Although first reported in 1973, immune heparin-induced thrombocytopenia (HIT) remains one of the most potentially devastating and frequent adverse drug reactions encountered by physicians. This Fourth Edition reinforces its standing as the leading guide to the accurate diagnosis and management of HIT by identifying key signs and symptoms of this disorder and providing clear intervention... |
 | Chemistry and Biology of Heparin and Heparan Sulfate The chemistry, biochemistry and pharmacology of heparin and heparan sulfate have been and continue to be a major scientific undertaking - heparin and its derivative remain important drugs in clinical practice. Chemistry and Biology of Heparin and Heparan Sulfate provides readers with an insight into the chemistry, biology and clinical applications of heparin and heparan sulfate and examines... |
 | Heparin-Binding Proteins by H. Edward Conrad This book describes the complex structures of heparins and heparan sulfates (heparinoids) and how they are generated by their biosynthetic pathways. The book also details the methodologies for studying these structures and their cellular metabolism. Heparin-Binding Proteins introduces the general nature of interactions between heparinoids and proteins, and presents the role for these structures... |
| Enzymes Involved in Biosynthesis and Degradation of Heparin-Related Polysaccharides (Comprehensive Summaries of Uppsala Dissertations, 841) by Dagmar Sandback Pikas | |
| Additives to Blood Collection Devices: Heparin: Tentative Standard (1988) (Additives to Blood Collection Devices) by National Committee for Clinical Laborato | |
| Heparin-Induced Thrombocytopenia Revised and Expanded by Warkentin/Grein | |
| Thromboprophylaxis Handbook - Thromboprophylaxis with Low-molecular-weight Heparins (LMWH) by D. Warwick, D. Gozzard | |
| Effects of fibrinolytic inhibitors and heparin on induced intravascular coagulation (Acta Physiologica Scandinavica. Supplementum) by Sam Nordstrom | |
| Covalent coupling of heparin to synthetic polymer surfaces (Massachusetts Institute of Technology. Dept. of Chemical Engineering. Thesis. 1977. Ph. D) by Ali Kemal Dincer |
| © 2008 BrightSurf.com |